Welcome to our dedicated page for Kewaunee Scienti news (Ticker: KEQU), a resource for investors and traders seeking the latest updates and insights on Kewaunee Scienti stock.
Kewaunee Scientific Corporation (NASDAQ: KEQU) is a manufacturing company specializing in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. This news page aggregates company announcements, earnings releases, and other disclosures so readers can follow developments that affect KEQU stock and Kewaunee’s operations.
Recent news has focused on quarterly and annual financial results, where Kewaunee reports performance for its domestic, international, and corporate segments and discusses trends in sales, profitability, and order backlog. The company also provides updates on non-GAAP metrics such as EBITDA, Segment EBITDA, Adjusted EBITDA, and adjusted net earnings, including the impact of acquisition and integration costs related to NuAire.
Investors and observers can also find coverage of capital structure and financing actions, including debt refinancing, early repayment of seller notes associated with the NuAire acquisition, and amendments to loan agreements. In addition, Kewaunee issues news about share repurchase program amendments and its approach to capital allocation.
Corporate governance and strategic matters appear in items such as board appointments, proxy-related communications, and disclosures about strategic investments in people, processes, and technology at the corporate level. Operational and commercial updates include participation in industry events like the Arablab Live trade show and information about Kewaunee’s global footprint, including its manufacturing facilities in Statesville, North Carolina and Bangalore, India and its sales offices in multiple countries.
By reviewing the KEQU news feed on this page, readers can track how Kewaunee communicates about its financial performance, acquisitions, international activities, and corporate initiatives over time.
Kewaunee Scientific Corporation (NASDAQ: KEQU) has announced plans to release its first quarter fiscal year 2026 financial results on September 10, 2025 after market close. The company, founded in 1906, is a global leader in laboratory, healthcare, and technical furniture products manufacturing.
Kewaunee's portfolio includes steel and wood casework, fume hoods, modular systems, and biological safety cabinets. The company operates manufacturing facilities in Statesville, North Carolina and Bangalore, India, with sales offices across the US, India, Saudi Arabia, and Singapore. Through its recently acquired subsidiary Nu Aire, the company also manufactures laboratory products in Minnesota and maintains partnerships in the Netherlands and China.
Kewaunee Scientific Corporation (NASDAQ: KEQU) reported strong financial results for Q4 and fiscal year 2025. Q4 sales reached $77.1 million, up 36.1% year-over-year, with net earnings of $4.85 million and diluted EPS of $1.63. The company's order backlog stood at $214.6 million as of April 30, 2025.
The company completed the acquisition of Nu Aire, Inc. on November 1, 2024, strengthening its laboratory equipment portfolio. For the full fiscal year 2025, sales increased 18% to $240.5 million, with net earnings of $11.4 million. Adjusted for acquisition costs, fiscal year 2025 adjusted diluted EPS was $5.37, compared to $4.19 in the prior year.
The Domestic segment showed particularly strong performance with sales up 54.7% in Q4, while International segment sales increased by 3.9%. The company maintains a healthy financial position with $17.2 million in cash and a debt-to-equity ratio of 0.99-to-1.
Kewaunee Scientific (NASDAQ: KEQU) has announced an amendment to its share repurchase program on March 12, 2025. The Board of Directors has authorized the repurchase of an additional 100,000 shares of common stock, adding to the 11,176 shares still authorized under the existing program that began September 1, 2023.
The company temporarily paused repurchases to focus on the acquisition of Nu Aire, Inc., which closed on November 1, 2024, after repurchasing the maximum allowable shares under their prior credit agreement between October 2023 and April 2024. Share repurchases resumed on February 28, 2025.
The program's timing and amount will be determined by management based on capital needs, stock price, and market conditions. The company maintains flexibility to suspend or discontinue the program at any time.
Kewaunee Scientific (NASDAQ: KEQU) reported its Q3 FY2025 results with sales of $67.17 million, up 43.6% year-over-year. However, pre-tax earnings decreased 63.7% to $1.28 million, with diluted EPS falling to $0.45 from $0.85.
The quarter included costs related to the Nu Aire acquisition, completed on November 1, 2024. Adjusting for acquisition and integration costs of $2.51 million, adjusted pre-tax earnings were $3.79 million, up 7.8% YoY, with adjusted EPS of $1.09.
Key metrics include:
- Order backlog: $221.6 million (up from $152.3 million YoY)
- Domestic sales: $51.98 million (+63.6% YoY)
- International sales: $15.19 million (+1.2% YoY)
- Cash position: $12.34 million
- Debt-to-equity ratio: 1.29-to-1
The company's Domestic segment showed strong performance, while the International segment faced challenges due to customer site delays. Management remains focused on operational excellence and strategic growth initiatives.
Kewaunee Scientific (NASDAQ: KEQU) has announced it will release its third quarter fiscal year 2025 financial results on March 12, 2025 after market close. The results will be available on the company's website.
Founded in 1906, Kewaunee Scientific is a global leader in laboratory, healthcare, and technical furniture products manufacturing. The company operates manufacturing facilities in Statesville, North Carolina, and Bangalore, India. Through its recently acquired subsidiary Nu Aire, founded in 1971, the company has expanded its portfolio to include biological safety cabinets, CO2 incubators, and ultralow freezers. Nu Aire's facilities are located in Plymouth and Long Lake, Minnesota.
Kewaunee Scientific (NASDAQ: KEQU) reported Q2 FY2025 results with sales of $47.76M, down 5.3% YoY. Pre-tax earnings decreased 18.9% to $3.93M, while net earnings increased to $3.01M from $2.73M. The company's order backlog reached a historic high of $184.4M.
Domestic segment sales grew 6.5% to $36.41M, while International segment sales declined 30.1% to $11.36M due to construction delays in India. The company maintained strong liquidity with $29.66M cash on hand and reduced its debt-to-equity ratio to 0.59-to-1.
On November 1, 2024, Kewaunee completed the acquisition of Nu Aire, Inc., a leading manufacturer of biological safety cabinets and airflow products, incurring $2.3M in acquisition-related expenses during the quarter.
Kewaunee Scientific (NASDAQ: KEQU) announced it will release its second quarter fiscal year 2025 financial results on Wednesday, December 11, 2024 after market close. The results will be available on the company's website. Kewaunee Scientific, founded in 1906, is a global leader in laboratory, healthcare, and technical furniture products manufacturing, with headquarters in Statesville, North Carolina and manufacturing facilities in the US and India.
Kewaunee Scientific (NASDAQ: KEQU) has completed the acquisition of Nu Aire, a Minneapolis-based manufacturer of laboratory equipment, for $55 million. Nu Aire specializes in biological safety cabinets, airflow products, CO2 incubators, and related equipment serving life sciences, healthcare, and education sectors. The acquisition expands Kewaunee's product portfolio and market reach through Nu Aire's established distribution network. Bill Peters will continue as Nu Aire's President and join Kewaunee's corporate management team. The combined organization aims to enhance product offerings and leverage operational synergies for improved performance and sustainable growth.
Kewaunee Scientific (NASDAQ: KEQU) reported its Q1 FY2025 results. Key highlights include:
- Sales decreased 2.9% to $48,393,000
- Pre-tax earnings fell 28.8% to $2,430,000
- Net earnings decreased to $2,193,000
- Diluted EPS dropped to $0.74 from $0.86
- Order backlog increased to $159.4 million
- Domestic sales rose 0.3% to $35,523,000
- International sales declined 10.7% to $12,870,000
The company maintained a strong financial position with $25,186,000 in cash and a debt-to-equity ratio of 0.68-to-1. Despite challenges in the international segment due to project delays in India, the domestic segment showed improved performance. The company's CEO expressed confidence in another strong year based on the robust backlog and high quoting activity.